Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert-Jan Mulder

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nature Biotechnology|April 15, 2014
Acquiring orphansRogier Rooswinkel, Geert-Jan Mulder, Sander van Deventer
Nature Biotechnology|April 9, 2013
Building for big pharmaAsiya Giniatullina, Marco Boorsma, Geert-Jan Mulder, et al.
Progress in Retinal and Eye Research|January 13, 2024
Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investmentDmitrij Hristodorov, Tim Lohoff, Nanna Luneborg, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2009
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infectionOlanrewaju O Okusanya, Sujata M Bhavnani, Jeffrey Hammel, et al.
JAMA|May 26, 2018
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical TrialGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
The Lancet. Respiratory Medicine|May 25, 2019
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension studyGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
Nature|September 17, 2010
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaMarina Cavazzana-Calvo, Emmanuel Payen, Olivier Negre, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nature Biotechnology|April 15, 2014
Acquiring orphansRogier Rooswinkel, Geert-Jan Mulder, Sander van Deventer
Nature Biotechnology|April 9, 2013
Building for big pharmaAsiya Giniatullina, Marco Boorsma, Geert-Jan Mulder, et al.
Progress in Retinal and Eye Research|January 13, 2024
Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investmentDmitrij Hristodorov, Tim Lohoff, Nanna Luneborg, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2009
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infectionOlanrewaju O Okusanya, Sujata M Bhavnani, Jeffrey Hammel, et al.
JAMA|May 26, 2018
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical TrialGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
The Lancet. Respiratory Medicine|May 25, 2019
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension studyGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
Nature|September 17, 2010
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaMarina Cavazzana-Calvo, Emmanuel Payen, Olivier Negre, et al.
Pageof 1